Kalshi seeks funding at $40bn valuation, up from $5bn last October
Regulated prediction market operator eyes Q3 close and a potential 2027 public debut
Briefing
- Kalshi's implied valuation has risen eightfold in roughly eight months, from $5bn in October 2025 to a targeted $40bn in the current round, making it the dominant regulated prediction market by implied scale.
- The company is in active talks to close the new funding round in Q3 2026, according to the Financial Times report that broke the story.
- Kalshi is eyeing a potential public debut in 2027, meaning this round would likely serve as the final or penultimate private raise before an IPO process.
- The valuation gap between Kalshi and rival Polymarket, which operates outside US regulation, is widening as institutional capital gravitates toward the regulated venue.
- A successful close at $40bn would position Kalshi as a direct challenger to established derivatives and sports-betting operators, broadening the competitive threat beyond crypto-native prediction markets.
Analysis
- CME's pending lawsuit against the CFTC over Kalshi's perpetual futures product creates a material legal overhang that caps the practical value of a $40bn pre-IPO round. If a court finds perpetual futures meet Dodd-Frank's swap definition, Kalshi's core product must be restructured or withdrawn, directly undermining the revenue base investors are valuing. The litigation could extend 12-24 months, meaning the 2027 IPO window opens into unresolved regulatory risk rather than a clean product slate.
- Kalshi's $40bn valuation, an eightfold increase in eight months, accelerates competitive pressure on regulated derivatives incumbents. CME, already litigating against Kalshi's product approval, faces the prospect of a well-capitalised rival that can outspend on lobbying, product development, and market-maker incentives in event-contract and political markets. Sports-betting operators with regulated US licenses, such as DraftKings and Flutter, face a new entrant with institutional capital and CFTC backing targeting adjacent wagering flows.
Historical Context
- Oct 2023
A federal court overturned CFTC's ban on Kalshi's political event contracts, establishing that prediction markets on elections are legal under the Commodity Exchange Act. That ruling is the legal foundation on which Kalshi's current product suite and valuation rest; CME's Dodd-Frank swap argument is an attempt to narrow that precedent.
- 2021
Robinhood's IPO priced at a $32bn valuation after rapid retail-driven growth; the stock halved within months as regulatory scrutiny of payment-for-order-flow and product limitations weighed on its multiple. Kalshi faces an analogous risk: a high private-round valuation entering a contested regulatory environment ahead of a public listing.
- 2015
Daily fantasy sports operators DraftKings and FanDuel raised at multi-billion valuations before a wave of state attorney-general actions forced product suspensions and restructuring. The precedent is relevant to prediction markets: regulatory re-classification mid-growth-cycle can compress valuations faster than the underlying business can adapt.
Connected Events
CME Group to sue CFTC over approval of perpetual futures
CME Group is suing the CFTC over its approval of Kalshi's perpetual futures, arguing the product meets Dodd-Frank's swap definition. The lawsuit is the single largest legal risk to the valuation thesis embedded in Kalshi's $40bn round.
Robinhood cuts 10% of workforce in management restructuring
Robinhood's 10% workforce reduction included a strategic note on prediction-market product velocity, with the prior implication flagging that Robinhood is positioning options, crypto, and prediction-market products against incumbents. A well-capitalised Kalshi at $40bn directly competes for the same retail prediction-market flow Robinhood is targeting.
Binance withdraws Greek MiCA application days before EU deadline
Binance's failure to secure EU MiCA licensing before the July 1 deadline illustrates how rapidly a high-valuation platform's operational base can be disrupted by adverse regulatory outcomes, a directly analogous risk for Kalshi if CME's Dodd-Frank litigation succeeds.
Further reading
See Indexa more often on Google
Mark Indexa as a preferred source — your Top Stories will surface more Indexa coverage.
